NEWTOWN, Pa.----CollaGenex Pharmaceuticals, Inc. today announced results of a Phase 2 dose-finding study designed to evaluate the safety and efficacy of Col-118 for the treatment of erythema.
From: biz.yahoo.com
CollaGenex Pharmaceuticals Announces Highly Positive Results of Phase 2 Dose-Finding Trial of Col-118 for the Treatment ...
Posted by Ruslan Abuzant at 6:02 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment